Search results for " prostate cancer"

showing 10 items of 83 documents

Can side-specific biopsy findings predict the side of nodal metastasis in clinically localized prostate cancer? Results from a multicenter prospectiv…

2013

Background To evaluate the correlation between the side of positive biopsy (Bx) and the risk of lymph-node metastases (LNMs) on each side and to quantify the risk of contralateral LNMs in patients with unilateral positive biopsy. Methods We analyzed the outcomes of 1599 patients with complete data regarding the sides of positive Bx and LN (lymph-node). By dividing each prostate into two separate sides, we assessed the accuracy of the side-specific Bx details in determining the side of positive nodes; the area under the receiver-operating characteristic (ROC) (AUCs) was used. For patients with unilateral positive Bx, we assessed the risk of homolateral and contralateral LNMs according to the…

AdultMaleRiskmedicine.medical_specialtyProstate biopsyPelviLymph node metastasis; Pelvic lymph node dissection; Prostate biopsy; Prostate cancer; Radical prostatectomyPelvisProstate biopsyProstate cancerLymph node metastasiProstateBiopsymedicineHumansProspective StudiesProspective surveyAgedAged 80 and overProstatectomyLymph node metastasisProstate cancermedicine.diagnostic_testbusiness.industryNodal metastasisProstatic NeoplasmsLymph NodeLymphatic MetastasiGeneral MedicineMiddle Agedmedicine.diseaseRadical prostatectomySurgeryPelvic lymph node dissectionDissectionProspective Studiemedicine.anatomical_structureROC CurveOncologyLymphatic MetastasisProstatic NeoplasmLymph Node ExcisionSurgeryRadiologyLymph NodesBiopsy Large-Core NeedlebusinessBiopsy findingsHuman
researchProduct

Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey

2018

Introduction: The urological community's opinion over focal therapy (FT) for prostate cancer (PCa) has never been assessed. Our aim was to investigate the current opinion on FT in the European urological community. Methods: A 25 -item questionnaire was devised according to the Cherries checklist and distributed through SurveyMonkey using a web link from November 2016 to October 2017. After a pilot validation (n=40 urologists), the survey was sent through EAU and 9 other national European urological societies mailing list. Twitter was also used. Results: We received 484 replies from 51 countries. Almost half (44.8%, n=217) stated FT would represent a step forward, and 52.0% (n=252) would sug…

AdultMalemedicine.medical_specialtyMultivariate analysisUrology030232 urology & nephrologyClinical practiceClinical practice; European Association of Urology; Focal therapy; Prostate cancer; Survey; Young Academic Urologists03 medical and health sciencesProstate cancer0302 clinical medicineFocal therapySurveys and QuestionnairesmedicineHumansIn patientSurveyProstate cancerbusiness.industryProstatic NeoplasmsNegative opinionMiddle AgedUrology & NephrologyPrognosismedicine.diseaseChecklistEuropeFocal therapyClinical PracticeEuropean Association of UrologyYoung Academic UrologistsCross-Sectional StudiesOncology030220 oncology & carcinogenesisFamily medicineEAU-YAU Prostate Cancer Working Partybusiness1112 Oncology And CarcinogenesisFollow-Up StudiesUrologic Oncology: Seminars and Original Investigations
researchProduct

The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer.

2016

Introduction Prostatic Specific Antigen (PSA), Bacillus Calmette-Guerin (BCG) increase after intravesical BCG has been reported. The need of prostate biopsy in these patients is object of debate. The aim of our study was to evaluate the effect of intravesical therapy on PSA after transurethral resection (TUR) of nonmuscle-invasive bladder cancer (NMIBC). Materials and methods Patients undergoing intravesical chemotherapy or immunotherapy for NMIBC were entered. PSA was measured before TUR, before the first and after the sixth instillation, 30 and 90 days after the last instillation. Patients with PSA ≥4 ng/ml or palpable prostate nodule were excluded. Results Out of 130 patients, 105 were e…

Adultmedicine.medical_specialtyProstate biopsymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic Agents03 medical and health sciencesProstate cancer0302 clinical medicineAdjuvants ImmunologicBiopsyIntravesical instillation Prostate cancer PSAmedicineAdjuvant therapyCombined Modality TherapyHumansNeoplasm InvasivenessAgedAged 80 and overChemotherapyBladder cancermedicine.diagnostic_testbusiness.industryGeneral MedicineImmunotherapyMiddle AgedProstate-Specific Antigenmedicine.diseaseCombined Modality TherapyAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccinebusinessUrologia
researchProduct

PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer

2020

68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT) is commonly used for restaging recurrent prostate cancer (PC) in European clinical practice. The goal of this study is to determine the optimum time for performing these PET/CT scans in a large cohort of patients by identifying the prostate-specific-antigen (PSA) and PSA kinetics thresholds for detecting and localizing recurrent PC. This retrospective analysis includes 581 patients with biochemical recurrence (BC) by definition. The performance of 68Ga-PSMA-11 PET/CT in relation to the PSA value at the scan time as well as PSA kinetics was assessed by the receiver-operating-characteristic-curve (ROC) generated by plottin…

Biochemical recurrenceCancer Researchmedicine.medical_treatment68Gallium-PSMA PET/CTurologic and male genital diseaseslcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicine<sup>68</sup>gallium-psma pet/ctprostate-specific-antigenPSA kinetics thresholdsbiochemical recurrenceMedicineoptimal cutoff levelPET-CTPsa kineticsbusiness.industryProstatectomylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensprostate cancermedicine.diseaseRadiation therapyProstate-specific antigenOncology030220 oncology & carcinogenesisRecurrent prostate cancerbusinessNuclear medicineCancers
researchProduct

10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients.

2020

Purpose The primary aim of this multicenter retrospective analysis is to examine the role of(18)F-choline PET/CT as a diagnostic tool for staging and restaging prostate cancer (PCa) in a large population in the light of 10 years of clinical experience. A secondary aim of the study is to produce data on the predictors of a positive(18)F-choline PET/CT result in the setting of PCa primaries and biochemical recurrences. Materials and Methods This multicenter retrospective cohort study is based on data collected by 9 Italian nuclear medicine departments. Between October 2008 and September 2019, 3343 men underwent(18)F-choline PET/CT scans before receiving definitive treatments for a primary PCa…

Biochemical recurrenceMalemedicine.medical_specialtyProstate biopsyrecurrencePET/CTcholine; PET/CT; prostate cancer; recurrence; staging030218 nuclear medicine & medical imagingCholine03 medical and health sciencesProstate cancer0302 clinical medicineSettore MED/36ProstatePositron Emission Tomography Computed Tomography80 and overMedicineHumansRadiology Nuclear Medicine and imagingTomographyCancer stagingAgedAged 80 and overPET-CTmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsRetrospective cohort studyGeneral MedicinestagingMiddle Agedmedicine.diseaseprostate cancerX-Ray ComputedProstate-specific antigenmedicine.anatomical_structurePET030220 oncology & carcinogenesisRadiologyNeoplasm GradingRadiopharmaceuticalsbusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedCT; choline; prostate cancer; recurrence; staging; Aged; Aged 80 and over; Choline; Humans; Male; Middle Aged; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tomography X-Ray ComputedCTClinical nuclear medicine
researchProduct

Radiation therapy after radical prostatectomy: what has changed over time?

2021

The role and timing of radiotherapy (RT) in prostate cancer (PCa) patients treated with radical prostatectomy (RP) remains controversial. While recent trials support the oncological safety of early salvage RT (SRT) compared to adjuvant RT (ART) in selected patients, previous randomized studies demonstrated that ART might improve recurrence-free survival in patients at high risk for local recurrence based on adverse pathology. Although ART might improve survival, this approach is characterized by a risk of overtreatment in up to 40% of cases. SRT is defined as the administration of RT to the prostatic bed and to the surrounding tissues in the patient with PSA recurrence after surgery but no …

Biochemical recurrenceOncologymedicine.medical_specialtyRD1-811medicine.medical_treatmentMedizinReviewDisease030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinebiochemical recurrencegenomic classifiersmedicineddc:610hormonal therapyProstatectomybusiness.industrysalvage radiotherapyprostate cancermedicine.diseaseRadiation therapyadjuvant radiotherapy; biochemical recurrence; genomic classifiers; hormonal therapy; prostate cancer; salvage radiotherapy030220 oncology & carcinogenesisHormonal therapySurgeryHormone therapybusinessadjuvant radiotherapyAdjuvant
researchProduct

The Catalytic Mechanism of Steroidogenic Cytochromes P450 from All-Atom Simulations: Entwinement with Membrane Environment, Redox Partners, and Post-…

2019

Cytochromes P450 (CYP450s) promote the biosynthesis of steroid hormones with major impact on the onset of diseases such as breast and prostate cancers. By merging distinct functions into the same catalytic scaffold, steroidogenic CYP450s enhance complex chemical transformations with extreme efficiency and selectivity. Mammalian CYP450s and their redox partners are membrane-anchored proteins, dynamically associating to form functional machineries. Mounting evidence signifies that environmental factors are strictly intertwined with CYP450s catalysis. Atomic-level simulations have the potential to provide insights into the catalytic mechanism of steroidogenic CYP450s and on its regulation by e…

Breast cancer; Cytochrome P450; Membrane modulation; Molecular dynamics; Phosphorylation; Prostate cancer; QM/MMCytochrome P450-Molecular dynamicslcsh:Chemical technology010402 general chemistryQM/MM01 natural sciencesCatalysislcsh:Chemistry03 medical and health scienceschemistry.chemical_compoundBreast cancerBiosynthesislcsh:TP1-1185PhosphorylationPhysical and Theoretical ChemistryPost-transcriptional regulation030304 developmental biologyGeneral Environmental Sciencechemistry.chemical_classification0303 health sciencesProstate cancerbiologyMechanism (biology)Membrane modulationCytochrome P450Ligand (biochemistry)0104 chemical sciencesCell biologyEnzymelcsh:QD1-999chemistryCYP17A1biology.proteinPhosphorylationCatalysts
researchProduct

Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide

2022

Introduction: This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted agents. Methods: We retrospectively enrolled metastatic castration resistant prostate cancer patients treated with androgen receptor targeted agents between December 2016 and January 2022. All patients experienced an oligoprogression (defined as the appearance and/or the progression of ⩽5 bone or nodal or soft tissue metastases) during treatment with androgen receptor targeted agents and received stereotactic body radiotherapy upon oligoprogre…

Cancer ResearchenzalutamideOncologyStereotactic body radiotherapyabirateronemetastatic castration resistant prostate cancerGeneral Medicineoligometastatic diseaseSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTumori Journal
researchProduct

Automated prostate gland segmentation based on an unsupervised fuzzy C-means clustering technique using multispectral T1w and T2w MR imaging

2017

Prostate imaging analysis is difficult in diagnosis, therapy, and staging of prostate cancer. In clinical practice, Magnetic Resonance Imaging (MRI) is increasingly used thanks to its morphologic and functional capabilities. However, manual detection and delineation of prostate gland on multispectral MRI data is currently a time-expensive and operator-dependent procedure. Efficient computer-assisted segmentation approaches are not yet able to address these issues, but rather have the potential to do so. In this paper, a novel automatic prostate MR image segmentation method based on the Fuzzy C-Means (FCM) clustering algorithm, which enables multispectral T1-weighted (T1w) and T2-weighted (T…

Computer scienceAutomated segmentation; Fuzzy C-Means clustering; Multispectral MR imaging; Prostate cancer; Prostate gland; Unsupervised machine learningMultispectral image02 engineering and technologyautomated segmentation; multispectral MR imaging; prostate gland; prostate cancer; unsupervised Machine Learning; Fuzzy C-Means clustering030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstate0202 electrical engineering electronic engineering information engineeringmedicineComputer visionSegmentationautomated segmentationunsupervised Machine LearningCluster analysisSettore ING-INF/05 - Sistemi Di Elaborazione Delle Informazionimedicine.diagnostic_testbusiness.industryINF/01 - INFORMATICAMagnetic resonance imagingmedicine.diseaseprostate cancerFuzzy C-Means clusteringmultispectral MR imagingmedicine.anatomical_structureUnsupervised learning020201 artificial intelligence & image processingArtificial intelligencebusinessprostate glandInformation SystemsMultispectral segmentation
researchProduct

Fully automatic multispectral MR image segmentation of prostate gland based on the fuzzy C-means clustering algorithm

2017

Prostate imaging is a very critical issue in the clinical practice, especially for diagnosis, therapy, and staging of prostate cancer. Magnetic Resonance Imaging (MRI) can provide both morphologic and complementary functional information of tumor region. Manual detection and segmentation of prostate gland and carcinoma on multispectral MRI data is not easily practicable in the clinical routine because of the long times required by experienced radiologists to analyze several types of imaging data. In this paper, a fully automatic image segmentation method, exploiting an unsupervised Fuzzy C-Means (FCM) clustering technique for multispectral T1-weighted and T2-weighted MRI data processing, is…

Computer scienceMultispectral imageFully automatic segmentation; Multispectral MR imaging; Prostate cancer; Prostate gland; Unsupervised fuzzy C-means clusteringFuzzy logic030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstatemedicineSegmentationComputer visionCluster analysismedicine.diagnostic_testbusiness.industryINF/01 - INFORMATICAMagnetic resonance imagingfully automatic segmentationImage segmentationmedicine.diseaseprostate cancermultispectral MR imagingunsupervised Fuzzy C-Means clusteringmedicine.anatomical_structureArtificial intelligencebusinessprostate gland030217 neurology & neurosurgery
researchProduct